Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
This article was originally published in Scrip
Executive Summary
Bayer and Johnson & Johnson's Xarelto (rivaroxaban) faced a further setback this week after Bayer announced that despite previous guidance it would not respond to the US FDA's rejection of the drug before the end of they year. Bayer shares have fallen by 4% in two days, to around €52.02 on December 8th, since the delay was announced.